Equillium Inc. Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Reuters
14 Jun
<a href="https://laohu8.com/S/EQ">Equillium Inc.</a> Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Equillium Inc. has announced a regulatory issue concerning its compliance with Nasdaq's Listing Rule 5550(a)(2). The company received a notice from Nasdaq indicating that its common stock had fallen below the minimum bid price of $1.00 per share for 30 consecutive business days, failing to meet the Minimum Bid Price Requirement. Initially given until June 11, 2025, to rectify this, the company has now been granted an additional 180 days, until December 8, 2025, to regain compliance. Equillium is actively monitoring its stock price and considering measures such as a reverse stock split to address the issue. The company's stock remains listed on the Nasdaq Capital Market under the symbol "EQ" for the time being.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-086155), on June 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10